Clinical trials: sponsored by Beijing InnoCare Pharma Tech Co., Ltd.
- Lead sponsor (exact) Beijing InnoCare Pharma Tech Co., Ltd.
- Funder type Industry (pharma, biotech, devices)
Advanced Solid Tumor
Evaluation of ICP-B381 in Patients With Advanced Solid Tumors
To evaluate the safety, tolerability, efficacy and pharmacokinetic characteristics of ICP-B381 in the trial participants of advanced solid tumors
- Trial name
- NCT07901413
- Testing
- ICP-B381
- Where
- China
- Volunteers
- 348 people
- Sponsor
- Beijing InnoCare Pharma Tech Co., Ltd.
Relapsed/Refractory Marginal Zone Lymphoma (MZL)
Orelabrutinib Plus ICP 248 vs Orelabrutinib for Relapsed/Refractory Marginal Zone Lymphoma
To evaluate the efficacy of olubrutinib combined with ICP-248 compared with the olubrutinib in the treatment of r/r MZL
- Trial name
- NCT07896590
- Testing
- Orelabrutinib, ICP-248
- Where
- 46 sites in China
- Volunteers
- 292 people
- Sponsor
- Beijing InnoCare Pharma Tech Co., Ltd.
Prurigo Nodularis (PN)
Study of the Efficacy and Safety of ICP-332 in Participants With Prurigo Nodularis
Evaluate the efficacy and safety of ICP-332 in participants with Prurigo Nodularis (PN)
- Trial name
- NCT07236099
- Testing
- ICP-322
- Where
- 43 sites in United States, China and 3 more
- Volunteers
- 135 people
- Sponsor
- Beijing InnoCare Pharma Tech Co., Ltd.
Relapsed or Refractory Mantle Cell Lymphoma (MCL)
A Phase 3 Study to Compare the Efficacy of ICP-248 in Combination With Orelabrutinib Versus Pirtobrutinib in Participants With Relapsed or Refractory Mantle Cell Lymphoma (r/r MCL).
This study aims to compare the efficacy and safety of ICP-248 in combination with orelabrutinib versus pirtobrutinib in patients with relapsed or refractory mantle cell lymphoma (r/r MCL).
- Trial name
- NCT07784101
- Testing
- ICP-248, Pirtobrutinib, Orelabrutinib
- Where
- 24 sites in China
- Volunteers
- 280 people
- Sponsor
- Beijing InnoCare Pharma Tech Co., Ltd.
Acute Myelogenous Leukemia, Myelodysplastic Syndromes (MDS)
ICP-248 in Combination With Azacitidine for the Treatment in Patients With Myeloid Malignancies
Evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of ICP-248 in combination with azacitidine in patients with acute myelogenous leukemia and Myelodysplastic Syndromes.
- Trial name
- NCT06656494
- Testing
- ICP-248, Azacitidine
- Where
- 22 sites in United States, Australia and 1 more
- Volunteers
- 266 people
- Sponsor
- Beijing InnoCare Pharma Tech Co., Ltd.
Primary Sjögren's Syndrome
A Study to Evaluate the Efficacy and Safety of ICP-488 in Participants With Primary Sjögren's Syndrome
This is a multicenter, randomized, double-blind, placebo-controlled Phase II clinical study to evaluate the efficacy and safety of ICP-488 in participants with primary Sjögren's syndrome (pSjS).
- Trial name
- NCT07727486
- Testing
- ICP-488 Tablets
- Where
- 22 sites in China
- Volunteers
- 240 people
- Sponsor
- Beijing InnoCare Pharma Tech Co., Ltd.
Relapsed or Refractory Mantle Cell Lymphoma (MCL)
A Study to Evaluate the Efficacy and Safety of ICP-248 in Subjects With Relapsed or Refractory Mantle Cell Lymphoma (APEX-06)
This is a single-arm, multi-center, open-label, phase 2 study to evaluate the efficacy and safety of ICP-248 in subjects with relapsed or refractory mantle cell lymphoma.
- Trial name
- NCT07082686
- Testing
- ICP-248
- Where
- 29 sites in China
- Volunteers
- 75 people
- Sponsor
- Beijing InnoCare Pharma Tech Co., Ltd.
Advanced Solid Tumor
Evaluation of ICP-B208 in Patients With Advanced Solid Tumors
To evaluate the safety, tolerability, efficacy and pharmacokinetic characteristics of ICP-B208 in the trial participants of unresectable advanced or metastatic solid tumors
- Trial name
- NCT07617493
- Testing
- ICP-B208
- Where
- China
- Volunteers
- 539 people
- Sponsor
- Beijing InnoCare Pharma Tech Co., Ltd.
Health Services Research
Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ICP-538 in Healthy Subjects
This is a Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Ascending Dose Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ICP-538 in Healthy Subjects
- Trial name
- NCT07535099
- Testing
- ICP-538 Tablets
- Where
- China
- Volunteers
- 104 people, healthy volunteers welcome
- Sponsor
- Beijing InnoCare Pharma Tech Co., Ltd.
Mantle Cell Lymphoma
A Study to Evaluate ICP-022 in Patients With R/R Mantle Cell Lymphoma (MCL)
The phase I/II clinical study is to investigate the safety, tolerability and pharmacokinetics/ pharmacodynamics of ICP-022.
- Trial name
- NCT03494179
- Testing
- ICP-022
- Where
- 31 sites in China
- Volunteers
- 106 people
- Sponsor
- Beijing InnoCare Pharma Tech Co., Ltd.
Part 1：r/r B-cell Malignancies, Part 2：B-cell Malignancies
A Study of Tyrosine Kinase Inhibitor Orelabrutinib (ICP-022) in Patients With r/r B-Cell Malignancies
This is a Phase I/II, multicenter, open-label study to evaluate the safety, efficacy, tolerability, and pharmacokinetics of a novel BTK inhibitor, Orelabrutinib (ICP-022) in Patients with B-cell malignancies.
- Trial name
- NCT04014205
- Testing
- Orelabrutinib (ICP-022)
- Where
- 36 sites in United States, Israel and 2 more
- Volunteers
- 81 people
- Sponsor
- Beijing InnoCare Pharma Tech Co., Ltd.
Cutaneous Lupus Erythematosus (CLE)
Evaluate the Efficacy and Safety of ICP-488 in Subjects With Cutaneous Lupus Erythematosus (CLE) Double-blind Study
This is a multicenter, randomized, double-blind, placebo-controlled Phase II clinical study to evaluate the efficacy and safety of ICP-488 in subjects with cutaneous lupus erythematosus (CLE).
- Trial name
- NCT07440537
- Testing
- ICP-488 Tablets
- Where
- 27 sites in China
- Volunteers
- 105 people
- Sponsor
- Beijing InnoCare Pharma Tech Co., Ltd.
Chronic Spontaneous Urticaria (CSU)
Study of the Efficacy and Safety of ICP-332 in Participants With Chronic Spontaneous Urticaria
The purpose of this study is to compare the efficacy and safety of ICP-332 in moderate to severe chronic spontaneous urticaria subjects inadequately controlled by second generation H1-antihistamines
- Trial name
- NCT07378527
- Testing
- ICP-332 Tablets
- Where
- 30 sites in China
- Volunteers
- 344 people
- Sponsor
- Beijing InnoCare Pharma Tech Co., Ltd.
Treatment-naїve Mantle Cell Lymphoma
A Randomized, Open-label, Multi-center, Phase III Study of Orelabrutinib in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) vs. R-CHOP Alone in Patients With Treatment-naїve Mantle Cell Lymphoma
To evaluate the efficacy of orelabrutinib combined with R-CHOP vs. R-CHOP alone in the treatment of treatment-naїve mantle cell lymphoma.
- Trial name
- NCT05051891
- Testing
- Orelabrutinib and R-CHOP, R-CHOP
- Where
- 22 sites in China
- Volunteers
- 3 people
- Sponsor
- Beijing InnoCare Pharma Tech Co., Ltd.
Plaque Psoriasis Patients
Efficacy, Safety, Pharmacokinetics of ICP-488 in Patients With Moderate to Severe Plaque Psoriasis
This is a multicenter, randomized, double-blind, placebo-controlled Phase III clinical study to evaluate the efficacy, safety, PK characteristics of ICP-488 in Chinese adults with moderate to severe plaque psoriasis.
- Trial name
- NCT06842199
- Testing
- ICP-488 Tablets
- Where
- 46 sites in China
- Volunteers
- 383 people
- Sponsor
- Beijing InnoCare Pharma Tech Co., Ltd.
Plaque Psoriasis
Efficacy and Safety of ICP-332 Versus Placebo in Participants With Moderate to Severe Plaque Psoriasis
The purpose of this study is to compare the efficacy and safety of ICP-332 to placebo in participants with moderate-to-severe plaque psoriasis.
- Trial name
- NCT07251998
- Testing
- ICP-332 Tablets
- Where
- China
- Volunteers
- 172 people
- Sponsor
- Beijing InnoCare Pharma Tech Co., Ltd.
Hematologic Malignancies
ICP-248 in Combination With Orelabrutinib in Treatment-naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (APEX-03)
Evaluate the safety, tolerability and pharmacokinetics of ICP-248 in Combination with Orelabrutinib in Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
- Trial name
- NCT06378138
- Testing
- ICP-248, Orelabrutinib
- Where
- 53 sites in China
- Volunteers
- 226 people
- Sponsor
- Beijing InnoCare Pharma Tech Co., Ltd.
Relapsed/Refractory Marginal Zone Lymphoma
Efficacy and Safety of Orelabrutinib Combined With Rituximab Versus Lenalidomide Combined With Rituximab in Patients With Relapsed/Refractory Marginal Zone Lymphoma
Efficacy and Safety of Orelabrutinib Combined with Rituximab versus Lenalidomide Combined with Rituximab in Patients with Relapsed/Refractory Marginal Zone Lymphoma
- Trial name
- NCT06082102
- Testing
- Orelabrutinib, Rituximab, Lenalidomide
- Where
- 19 sites in China
- Volunteers
- 324 people
- Sponsor
- Beijing InnoCare Pharma Tech Co., Ltd.
Advanced Solid Tumors Harboring NTRK Fusion, Primary Central Nervous System Tumors Harboring NTRK Fusion
Study of ICP-723 in Patients With Advanced Solid Tumors or Primary Central Nervous System Tumors
A Multi-center, Non-Randomized, Open-Label Phase 2 Basket Clinical Trial to Evaluate ICP-723 in Patients with Advanced Solid Tumors or Primary Central Nervous System Tumors
- Trial name
- NCT05745623
- Testing
- ICP-723
- Where
- China
- Volunteers
- 70 people
- Sponsor
- Beijing InnoCare Pharma Tech Co., Ltd.
Hematological Malignancies
The Study of ICP-248 in Patients With Mature B-cell Malignancies
A Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of ICP-248 as Monotherapy or in Combination Therapy in Patients with Mature B-cell Malignancies.This study…
- Trial name
- NCT05728658
- Testing
- ICP-248, ICP-248+Orelabrutinib, ICP-248 +Rituximab
- Where
- 22 sites in China
- Volunteers
- 191 people
- Sponsor
- Beijing InnoCare Pharma Tech Co., Ltd.